Related references
Note: Only part of the references are listed.Immunotherapy for Nonmelanoma Skin Cancer: Facts and Hopes
Sophia Z. Shalhout et al.
CLINICAL CANCER RESEARCH (2022)
Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
Adel Naimi et al.
CELL COMMUNICATION AND SIGNALING (2022)
The evolutionary legacy of immune checkpoint inhibitors
Itishree Kaushik et al.
SEMINARS IN CANCER BIOLOGY (2022)
Talimogene laherparepvec resulting in near-complete response in a patient with treatment-refractory Merkel cell carcinoma
Michael A. Cilento et al.
AUSTRALASIAN JOURNAL OF DERMATOLOGY (2022)
A single arm phase 2 study of talimogene laherparepvec in patients with low-risk invasive cutaneous squamous cell cancer. interim analysis.
Clara N Curiel et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Advances in Cutaneous Squamous Cell Carcinoma Management
Carrick Burns et al.
CANCERS (2022)
A Phase I Trial of Talimogene Laherparepvec in Combination with Neoadjuvant Chemotherapy for the Treatment of Nonmetastatic Triple-Negative Breast Cancer
Hatem Soliman et al.
CLINICAL CANCER RESEARCH (2021)
Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial
R. Dummer et al.
NATURE MEDICINE (2021)
Cytokine-Coding Oncolytic Adenovirus TILT-123 Is Safe, Selective, and Effective as a Single Agent and in Combination with Immune Checkpoint Inhibitor Anti-PD-1
Riikka Havunen et al.
CELLS (2021)
A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer
Megumi Kai et al.
SCIENTIFIC REPORTS (2021)
Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma
Josep Malvehy et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Oncolytic Virotherapy for Cancer: Clinical Experience
Shyambabu Chaurasiya et al.
BIOMEDICINES (2021)
MASTERKEY-265: A phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB-IVM1c melanoma (MEL)
A. Ribas et al.
ANNALS OF ONCOLOGY (2021)
Recent Advances in the Treatment of Melanoma
Brendan D. Curti et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609
Ahmad A. Tarhini et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Early safety from a phase I, multicenter, open-label clinical trial of talimogene laherparepvec (T-VEC) injected (inj) into liver tumors in combination with pembrolizumab (pem).
J. Randolph Hecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pre-treated anti-PD-1 refractory Merkel cell carcinoma successfully treated with the combination of PD-1/PD-L1 axis inhibitors and TVEC: a report of two cases
R. Knackstedt et al.
ANNALS OF ONCOLOGY (2019)
Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III- IV melanoma
Robert H. Andtbacka et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Oncolytic Tanapoxvirus Expressing Interleukin-2 is Capable of Inducing the Regression of Human Melanoma Tumors in the Absence of T Cells
Tiantian Zhang et al.
CURRENT CANCER DRUG TARGETS (2018)
A phase II study of talimogene laherparepvec followed by talimogene laherparepvec plus nivolumab in refractory T cell and NK cell lymphomas, cutaneous squamous cell carcinoma, Merkel cell carcinoma, and other rare skin tumors (NCI #10057).
Ann W. Silk et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma
Jason Chesney et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series
Lillian Sun et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Immunotherapy for Merkel cell carcinoma: a turning point in patient care
Isaac S. Chan et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
352PEarly safety from a phase I, multicenter, open-label, dose de-escalation study of talimogene laherparepvec (T-VEC) in Japanese patients (pts) with unresectable stage IIIB-IV melanoma (MEL)
N Yamazaki et al.
ANNALS OF ONCOLOGY (2018)
Tanapoxvirus lacking a neuregulin-like gene regresses human melanoma tumors in nude mice
Tiantian Zhang et al.
VIRUS GENES (2017)
Neutralization of matrix metalloproteinase-9 potentially enhances oncolytic efficacy of tanapox virus for melanoma therapy
Tiantian Zhang et al.
MEDICAL ONCOLOGY (2017)
Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy
Zuqiang Liu et al.
NATURE COMMUNICATIONS (2017)
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
Antoni Ribas et al.
CELL (2017)
Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors
Reinhard Dummer et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy
Frederick J. Kohlhapp et al.
CLINICAL CANCER RESEARCH (2016)
Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2016)
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
A. M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Genomic Classification of Cutaneous Melanoma
Rehan Akbani et al.
CELL (2015)
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Robert H. I. Andtbacka et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma
John F. Thompson et al.
ANNALS OF SURGICAL ONCOLOGY (2015)
The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594)
Caroline J. Breitbach et al.
ONCOLYTIC VIROTHERAPY (2015)
Therapeutic Improvement of a Stroma-Targeted CRAd by Incorporating Motives Responsive to the Melanoma Microenvironment
Diego L. Viale et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2013)
Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor-Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma
Neil N. Senzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Oncolytic viruses in cancer therapy
Markus J. V. Vaha-Koskela et al.
CANCER LETTERS (2007)
A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor
Jennifer C. C. Hu et al.
CLINICAL CANCER RESEARCH (2006)
ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties
BL Liu et al.
GENE THERAPY (2003)
Oncolytic biotherapy: a novel therapeutic platform
LK Hawkins et al.
LANCET ONCOLOGY (2002)
Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor
M Toda et al.
MOLECULAR THERAPY (2000)
Share Paper
